Securing Substantial Capital Through Nasdaq Listing and Establishing an Independent Path

Kardium (Kardigan, KARD), a cardiovascular-focused bio-pharmaceutical company, is pursuing a $320.3 million IPO on the Nasdaq Global Market, based on the midpoint of the proposed price range. The offering consists of 23.3 million shares priced between $14 and $16 per share, with the potential to increase to $369.1 million if the underwriters exercise their option. Despite already holding $287.1 million in cash, Kardium is seeking additional funding to independently advance its late-stage clinical trials and commercialization efforts, maximizing its corporate value rather than relying on external licensing.

Accelerating Clinical Trials of Danicamtiv, a Key Pipeline Asset for Genetic Dilated Cardiomyopathy

Approximately $80 million to $90 million of the proceeds will be allocated to the Phase 2b/3 clinical trial of danicamtiv, a drug candidate for genetic dilated cardiomyopathy. Danicamtiv is a cardiac myosin activator that aims to restore the contractile function of weakened heart muscles caused by genetic defects. The market for genetic cardiomyopathy is projected to grow rapidly to $8.67 billion by 2035, but there is a lack of therapies that target the underlying cause. Kardium aims to differentiate itself from Rocket Pharmaceuticals' gene therapy by developing an oral, precision medicine for this indication.

Targeting the Non-Pharmacological Landscape of CAVS with the Introduction of Ataciguat

Kardium will also allocate $80 million to $90 million to support the Phase 2b and Phase 3 trials of ataciguat, which has been licensed from Sanofi and the Mayo Clinic. Ataciguat targets calcific aortic valve stenosis, a condition for which there are currently no approved drugs, leaving patients reliant on invasive procedures such as transcatheter aortic valve replacement (TAVR). If successful, ataciguat is expected to be the first-in-class drug therapy, potentially capturing a significant portion of the $17.2 billion annual surgical market.

Diversified Cardiovascular Portfolio Including Tonlamarsen, Licensed from Ionis

Kardium will also invest $40 million to $50 million in the Phase 2 trial of tonlamarsen, a hypertension treatment licensed from Ionis Pharmaceuticals. Tonlamarsen is an antisense oligonucleotide that inhibits the production of angiotensinogen, targeting severe hypertension. While previous clinical trials showed modest direct blood pressure reduction, they were successful in improving key biomarkers, and further studies are underway. This diversified late-stage pipeline helps to mitigate the risks associated with drug development.

Experienced Leadership with a Proven Track Record, Building on the Success of MyoKardia

Kardium is led by Tassos Gianakakos, CEO, who previously led the development of camzyos, a heart failure treatment, at MyoKardia and secured FDA approval in 2022. MyoKardia was acquired by Bristol Myers Squibb (BMS) for $13.1 billion in 2020, demonstrating its commercial success. The management team's proven expertise in regulatory approvals and drug development significantly increases the likelihood of clinical success for danicamtiv and ataciguat. Investors are watching to see if Kardium can replicate the success of MyoKardia and establish itself as a leading player in the cardiovascular space.